[go: up one dir, main page]

WO2004081043A3 - Baff mutants with at least one amino acid substitution and methods of their production - Google Patents

Baff mutants with at least one amino acid substitution and methods of their production Download PDF

Info

Publication number
WO2004081043A3
WO2004081043A3 PCT/US2004/006779 US2004006779W WO2004081043A3 WO 2004081043 A3 WO2004081043 A3 WO 2004081043A3 US 2004006779 W US2004006779 W US 2004006779W WO 2004081043 A3 WO2004081043 A3 WO 2004081043A3
Authority
WO
WIPO (PCT)
Prior art keywords
baff
amino acid
acid substitution
mutants
production
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2004/006779
Other languages
French (fr)
Other versions
WO2004081043A2 (en
Inventor
John R Desjarlais
Eugene Zhukovsky
Adam Read Thomason
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xencor Inc
Original Assignee
Xencor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/338,083 external-priority patent/US20030166559A1/en
Application filed by Xencor Inc filed Critical Xencor Inc
Priority to CA002523776A priority Critical patent/CA2523776A1/en
Priority to EP04718010A priority patent/EP1606312A2/en
Priority to AU2004220078A priority patent/AU2004220078A1/en
Publication of WO2004081043A2 publication Critical patent/WO2004081043A2/en
Publication of WO2004081043A3 publication Critical patent/WO2004081043A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Toxicology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The invention relates to BAFF protein mutants carrying at least one amino acid substitution at one position having dominant negative antagonist activity, receptor antagonist activity and agonist activity and nucleic acids encoding these proteins. The invention further relates to the use of the BAFF protein mutants in the treatment of BAFF or APRIL-related disorders.
PCT/US2004/006779 2003-01-06 2004-03-05 Baff mutants with at least one amino acid substitution and methods of their production Ceased WO2004081043A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002523776A CA2523776A1 (en) 2003-03-07 2004-03-05 Baff mutants with at least one amino acid substitution and methods of their production
EP04718010A EP1606312A2 (en) 2003-03-07 2004-03-05 Baff mutants with at least one amino acid substitution and methods of their production
AU2004220078A AU2004220078A1 (en) 2003-03-07 2004-03-05 BAFF mutants with at least one amino acid substitution and methods of their production

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US10/338,083 US20030166559A1 (en) 2002-01-04 2003-01-06 Dominant negative proteins and methods thereof
US45270703P 2003-03-07 2003-03-07
US60/452,707 2003-03-07
US52388003P 2003-11-20 2003-11-20
US60/523,880 2003-11-20
US52810403P 2003-12-08 2003-12-08
US60/528,104 2003-12-08

Publications (2)

Publication Number Publication Date
WO2004081043A2 WO2004081043A2 (en) 2004-09-23
WO2004081043A3 true WO2004081043A3 (en) 2004-12-29

Family

ID=35351878

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/006779 Ceased WO2004081043A2 (en) 2003-01-06 2004-03-05 Baff mutants with at least one amino acid substitution and methods of their production

Country Status (4)

Country Link
EP (1) EP1606312A2 (en)
AU (1) AU2004220078A1 (en)
CA (1) CA2523776A1 (en)
WO (1) WO2004081043A2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7399829B2 (en) 2002-01-04 2008-07-15 Xencor, Inc. Variants of RANKL protein
US7381792B2 (en) 2002-01-04 2008-06-03 Xencor, Inc. Variants of RANKL protein
US7553930B2 (en) 2003-01-06 2009-06-30 Xencor, Inc. BAFF variants and methods thereof
US20050130892A1 (en) * 2003-03-07 2005-06-16 Xencor, Inc. BAFF variants and methods thereof
WO2005113598A2 (en) * 2004-05-21 2005-12-01 Xencor, Inc. Tnf super family members with altered immunogenicity
AU2005295713B2 (en) * 2004-10-13 2011-06-16 The Washington University Use of BAFF to treat sepsis
KR20080074120A (en) 2005-10-13 2008-08-12 휴먼 게놈 사이언시즈, 인코포레이티드 Methods and compositions for use in treatment of patients with autoantibody positive diseases
WO2007062090A2 (en) 2005-11-23 2007-05-31 Genentech, Inc. Methods and compositions related to b cell assays
WO2013171296A1 (en) 2012-05-16 2013-11-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Diagnostic and treatment of sarcoidosis
CZ2012561A3 (en) * 2012-08-22 2013-10-23 Masarykova Univerzita B-cell activating factor for increase of mucosal immunity of suckling infants and composition containing thereof
WO2014124280A1 (en) 2013-02-08 2014-08-14 Institute For Myeloma & Bone Cancer Research Improved diagnostic, prognostic, and monitoring methods for multiple myeloma, chronic lymphocytic leukemia, and b-cell non-hodgkin lymphoma
EP2971077B1 (en) 2013-03-15 2019-05-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Method and pharmaceutical composition for use in the treatment and prediction of myocardial infarction
ES2898329T3 (en) 2016-01-12 2022-03-07 Oncotracker Inc Improved methods for monitoring the immune status of a subject
CA3022481A1 (en) * 2016-05-16 2017-11-23 James Richard BERENSON Methods for monitoring immune status of a subject
US11635435B2 (en) 2017-06-13 2023-04-25 Oncotracker, Inc. Diagnostic, prognostic, and monitoring methods for solid tumor cancers

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000043032A2 (en) * 1999-01-25 2000-07-27 Biogen, Inc. Baff, inhibitors thereof and their use in the modulation of b-cell response
WO2002018620A2 (en) * 2000-08-15 2002-03-07 Human Genome Sciences, Inc. Neutrokine-alpha and neutrokine-alpha splice variant

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000043032A2 (en) * 1999-01-25 2000-07-27 Biogen, Inc. Baff, inhibitors thereof and their use in the modulation of b-cell response
WO2002018620A2 (en) * 2000-08-15 2002-03-07 Human Genome Sciences, Inc. Neutrokine-alpha and neutrokine-alpha splice variant

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS, XP002289894, Retrieved from the Internet <URL:http://www.xencor.com/news/releases/1282004-91.html> [retrieved on 20040721] *
KAWASAKI A ET AL: "Analysis on the association of human BLYS (BAFF, TNFSF13B) polymorphisms with systemic lupus erythematosus and rheumatoid arthritis.", GENES AND IMMUNITY, vol. 3, no. 7, November 2002 (2002-11-01), pages 424 - 429, XP009034180, ISSN: 1466-4879 *
KIM HO MIN ET AL: "Crystal structure of the BAFF-BAFF-R complex and its implications for receptor activation.", NATURE STRUCTURAL BIOLOGY, vol. 10, no. 5, May 2003 (2003-05-01), pages 342 - 348, XP002289896, ISSN: 1072-8368 *
LIU YINGFANG ET AL: "Crystal structure of sTALL-1 reveals a virus-like assembly of TNF family ligands", CELL, CELL PRESS, CAMBRIDGE, NA, US, vol. 108, no. 3, 8 February 2002 (2002-02-08), pages 383 - 394, XP002286032, ISSN: 0092-8674 *

Also Published As

Publication number Publication date
WO2004081043A2 (en) 2004-09-23
AU2004220078A1 (en) 2004-09-23
EP1606312A2 (en) 2005-12-21
CA2523776A1 (en) 2004-09-23

Similar Documents

Publication Publication Date Title
WO2004081043A3 (en) Baff mutants with at least one amino acid substitution and methods of their production
WO2005063820A3 (en) Il-7 fusion proteins
WO2003057856A3 (en) Dominant negative proteins and methods thereof
WO2008060813A3 (en) High affinity antibody antagonists of interleukin-13 receptor alpha 1
WO2002008285A3 (en) Il-17 molecules and uses thereof
WO2001064889A3 (en) Tnf-alpha variants for the treatment of tnf-alpha related disorders
AU2002252436A1 (en) Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
EP2083018A3 (en) Compositions and methods relating to STOP-1
WO2008049098A3 (en) ANTIBODY ANTAGONISTS OF INTERLEUKIN-13 RECEPTOR α1
WO2003016551A3 (en) Novel salicylic acid-binding protein encoding nucleic acid, sabp2, and methods of use thereof
WO2006034106A3 (en) Baff variants and methods therof
WO2000068364A3 (en) Mutations in nucleic acid molecules encoding 11-cis retinol dehydrogenase, the mutated proteins, and uses thereof
AU2002364691A1 (en) Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
WO2005035564A3 (en) Protein based tnf-alpha variants for the treatment of tnf-alpha related disorders
WO2004089982A3 (en) April variants and methods thereof
AU2003241361A8 (en) Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
AU2003210945A1 (en) Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
AU2003251293A8 (en) Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
WO2004018702A3 (en) Nphp nucleic acids and proteins
AU2003217864A1 (en) Isolated human ras-like proteins, nucleic acid molecules encoding these human ras-like proteins, and uses thereof
AU2003222241A8 (en) Isolated human enzyme proteins, nucleic acid molecules encoding human enzyme proteins, and uses thereof
AU2003213720A8 (en) Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
AU2003213721A8 (en) Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
AU2003235476A8 (en) Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
AU2002306963A1 (en) Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004220078

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2004718010

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2523776

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 2004718010

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2004220078

Country of ref document: AU

Date of ref document: 20040305

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004220078

Country of ref document: AU

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)